LYPD3

LYPD3 詳細

英語名Ly6/PLAUR domain-containing protein 3市販薬剤の数0
治験薬の数1ターゲットの別称C4.4A,GPI-Anchored Metastasis-Associated Protein Homolog,2310061G07Rik,GPI-Anchored Metastasis-Associated Protein C4.4A Homolog,MIG-C4,UNQ491/PRO1007,Ly6/PLAUR domain-containing protein 3,LYPD3,Matrigel-Induced Gene C4 Protein,LY6/PLAUR Domain Containing 3
研究&開発段階Phase 1 Clinical
英語名Ly6/PLAUR domain-containing protein 3
ターゲットの別称C4.4A,GPI-Anchored Metastasis-Associated Protein Homolog,2310061G07Rik,GPI-Anchored Metastasis-Associated Protein C4.4A Homolog,MIG-C4,UNQ491/PRO1007,Ly6/PLAUR domain-containing protein 3,LYPD3,Matrigel-Induced Gene C4 Protein,LY6/PLAUR Domain Containing 3
市販薬剤の数0
治験薬の数1
研究&開発段階Phase 1 Clinical

LYPD3 製品リスト

  • 属性

    Protein (2)

  • 製品ライブラリ

    オンライン (2)

  • Human (1)Mouse (1)

  • タグ

    His Tag (2)

  • マーカー

    Unconjugated (2)

製品番号発現システム製品説明タンパク質の構造純度特性
Human
HEK293
Human LYPD3 / C4.4A Protein, His Tag
Mouse
HEK293
Mouse LYPD3 / C4.4A Protein, His Tag (MALS verified)
総数量2
  • 1

LYPD3バックグランド

Ly6/PLAUR domain-containing protein 3 (LYPD3) is also known as MIG-C4 ,C4.4A, GPI-anchored metastasis-associated protein C4.4A homolog and Matrigel-induced gene C4 protein,which is a cell membrane protein containing two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. LYPD3 is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. LYPD3 play a role in supporting cell migration and it is not only probably involved in urothelial cell-matrix interactions, but also in tumor progression.

LYPD3分子の別称

LYPD3,MIG-C4,C4.4A

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Lupartumab amadotinBAY-1129980Phase 1 ClinicalBayer AGNeoplasms
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8